Table 2 Summary of cases reported in literature of GBS with vision loss due to Papilledema
From: Acute vision loss in Guillain–Barré syndrome: A case series and review of literature
Christina Doxaki et al. [11] | Kharbanda PS et al. [12] | Mathis S et al. [13] | Gross FJ et al. [14] | Hui-Jun Wen [15] | Our case | |
|---|---|---|---|---|---|---|
Variant of GBS | AIDP | AIDP | AIDP | AIDP | AIDP | AIDP |
Age (year)/ sex | 12/Female | 35/Female | 42/Male | 27/Female | 43/f | 25/Female |
Visual symptoms | Diminished vision | Diminished vision | Diminished vision | Transient visual obscuration | Blurred vision and Deterioration of near and distant vision and diplopia | Diminished vision |
Headache | Present | Present | Absent | Not mentioned | Absent | Present |
Signs of dysautonomia | Present | Present | Absent | Not mentioned | Absent | Present |
BCVA (RE and LE) | Reduced Reduced | PL PL | Reduced Reduced | RE-20/20 LE- 20/20 Enlarged blind spot | RE-20/30 LE- 20/25 | RE-6/60 LE-6/60 |
Papilledema | Present | Present | Present | Present | Present | Present |
Signs of raised ICP on Neuroimaging | Not mentioned | Present | Not mentioned | Not mentioned | Normal | Present |
CSF opening pressure | 460 mm of CSF | 420 mm of CSF | 150 mm of CSF | 310 mm of CSF | Not Mentioned | 280 mm of CSF |
ACD (CSF Proteins) | Present | – (20 mg/dl) | Present (435 mg/dl) | Present (325 mg/dl) | Present (862 mg/l) | Present (78 mg/dl) |
IVIG therapy | Given | Given | Given | – | Given | Given |
Other treatment given | Acetazolamide Corticosteroid | Acetazolamide Corticosteroid | Not mentioned | Not mentioned | Intravenous Dexamethasone and Mecobalamine | Mannitol Acetazolamide Corticosteroid |
Reassessment of vision | After 2 months | Not mentioned | After 1 year | After ~ 6 months | 3 weeks | After 1 month |
BCVA after treatment | RE-6/6 LE-6/6 | Not mentioned | RE-6/6 LE-6/6 | RE-20/20 LE-20/20 Blind spot normal sized | RE-6/6 LE-6/6 | RE-6/6 LE-6/6 |